86 listed sites: Bulgaria (5); Canada (6); France (5); Germany (6); Hungary (3); Italy (5); Poland (18); United Kingdom (5); United States (33) - 03 Nov `23Long-term povorcitinib study for nonsegmental vitiligo

Long-term povorcitinib study for nonsegmental vitiligo

Official title: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

Status: Closed to new participants

Description:

Incyte Corporation enrolled about 450 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People age 18 and older may qualify. The study is underway but is no longer accepting new participants.

Start date: November 27, 2023

Completion date: March 16, 2027

Organizer: Incyte Corporation

Contact: Incyte Medical Monitor

Link: https://clinicaltrials.gov/study/NCT06113471

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Long-term povorcitinib study for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Polypodium leucotomos as an adjunct treatment for vitiligo?

    The tropical fern Polypodium leucotomos (also known as Polypodium aureum) and its relative Polypodium decumanumhave shown potential benefits for managing vitiligo and other auto...

  • Is vitiligo contagious?

    Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo i...

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...